Sarepta Therapeutics could get European marketing approval for Exondys 51 at any time which will boost sales. Meanwhile, the company has great growth and is advancing other drugs through its pipeline.
Sarepta Therapeutics stock continues in a strong uptrend on Exondys 51.
Sarepta Therapeutics reported its last quarterly earnings data on October 25, 2017. The company reported EPS of ($0.20) versus the ($0.86) estimate. Revenue also beat coming in at $45.95 million versus the $41.29 million estimate.
Continue reading “Sarepta Therapeutics In Strong Uptrend From Exondys 51”
BeiGene stock has large players volume exploding higher. The company reported eye-popping earnings and revenue beats this week.
BeiGene stock has exploding large players volume and the company reported the biggest earnings and revenue beats of any company this week. The beats were the result of the Celgene strategic collaboration.
Continue reading “BeiGene Stock Exploding Large Players Volume On Candle Over Candle”
The day’s top news stories from stocks on the GuerillaStockTrading watch list.
Continue reading “Top News Stories November 14 2017”
Deciphera Pharmaceuticals will likely be pumped by the IPO underwriters soon now that the quiet period has ended.
Deciphera Pharmaceuticals’ quiet period ended on Tuesday, November 7, 2017. The brokerages that served as underwriters are working on research reports and will likely release those reports and analyst ratings on this company soon. In other words, the pump of this stock should start any week now. Please review this lesson on institutional traders and market makers.
Continue reading “Deciphera Pharmaceuticals Quiet Period Ended This Week”
Intercept Pharmaceuticals stock sold off on an FDA warning letter at the end of the quarter. Since, large players volume has been rising while the stock has formed a basing pattern.
Intercept Pharmaceuticals has rising large players volume while the stock has formed a basing pattern. This is a very bullish technical setup.
Continue reading “Intercept Pharmaceuticals Rising Large Players Volume”
Verastem stock had a price target set 364% higher than its current price by Cantor Fitzgerald. Cantor Fitzgerald has a buy rating on the stock.
Verastem is on track for duvelisib NDA in Q1 2018, to include accelerated approval request for follicular lymphoma. Duvelisib is a dual inhibitor of two enzymes called phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. Both are associated with the growth and survival of malignant B cells and T cells.
Continue reading “Verastem Price Target Set 364 Percent Higher By Cantor Fitzgerald”
Incyte Corporation stock has rising large players volume in an Ascending Triangle pattern. The large players volume rising while Incyte has been consolidating is a bullish pattern.
Continue reading “Incyte Corporation Rising Large Players Volume in Ascending Triangle”
Sorrento Therapeutics Inc has bounced off its 61.8 percent Fibonacci retracement level.
Continue reading “Sorrento Therapeutics Inc Bounce Off 61.8 Percent Retracement”
ContraVir Pharmaceuticals stock had short covering ahead of a price target hike by Maxim Group. A new $4 price target was set by analysts at Maxim Group on Thursday, October 19, 2017, which represents a 451% upside from the previous close of $0.73. Maxim has a Buy rating on ContraVir Pharmaceuticals stock.
Continue reading “ContraVir Pharmaceuticals Short Covering On Maxim Price Hike”
Global Blood Therapeutics stock has excellent large players volume action. Large players volume is in an uptrend and is confirmed by the rising Twiggs Money Flow.
Global Blood Therapeutics stock has 11 Buy ratings from analysts. Price targets average to $55.73 which represents 71.73% upside from the previous closing price. Needham & Company, one of the most followed analyst firms because of their excellent record, set a price target on the stock today of $51 which is 57% upside from the previous close at $32.45.
Continue reading “Global Blood Therapeutics Rising Large Players Volume”